Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Cabozantinib and Nivolumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, CANOPY Trial

Trial Status: closed to accrual

This phase II trial tests how well cabozantinib and nivolumab works in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and has not responded to hormone treatment (castration resistant). Kinase inhibitors, such as cabozantinib, help slow or stop the spread of tumor cells by blocking the action of an abnormal protein that signals tumor cells to multiply. Nivolumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and nivolumab may kill more tumor cells in patients with metastatic castration-resistant prostate cancer.